Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Actas dermo-sifiliogr. (Ed. impr.) ; 111(10): 822-828, dic. 2020. tab
Article in Spanish | IBECS | ID: ibc-200930

ABSTRACT

Los medicamentos industriales comercializados para uso tópico oral son muy escasos y con vehículos poco adecuados. En consecuencia, frecuentemente hay que recurrir a preparados magistrales que permitan aplicar principios activos en vehículos diseñados especialmente para su aplicación en la mucosa oral. La formulación magistral también permite incluir varios principios activos en un mismo vehículo y prescribir fármacos actualmente en desabastecimiento, entre otras ventajas. Describimos las principales fórmulas magistrales para el tratamiento de la patología de la mucosa oral más frecuente


Commercial topical medications for oral conditions are scarce and the vehicles used are not very suitable. Therefore, formulations containing active ingredients in vehicles specially designed for oral application must often be prepared. Drug compounding offers other advantages, including the possibility of combining several active ingredients in a single vehicle and prescribing drugs that are in short supply. In this article, we describe the main pharmaceutical formulations used to treat the most common diseases of the oral mucosa


Subject(s)
Humans , Mouth Mucosa/drug effects , Mouth Mucosa/pathology , Pharmaceutical Preparations/administration & dosage , Administration, Topical , Lichen Planus/epidemiology , Adrenal Cortex Hormones/administration & dosage , Tongue, Hairy/epidemiology , Cheilitis/epidemiology , Xerostomia/epidemiology
2.
Actas Dermosifiliogr (Engl Ed) ; 111(10): 822-828, 2020 Dec.
Article in English, Spanish | MEDLINE | ID: mdl-32910921

ABSTRACT

Commercial topical medications for oral conditions are scarce and the vehicles used are not very suitable. Therefore, formulations containing active ingredients in vehicles specially designed for oral application must often be prepared. Drug compounding offers other advantages, including the possibility of combining several active ingredients in a single vehicle and prescribing drugs that are in short supply. In this article, we describe the main pharmaceutical formulations used to treat the most common diseases of the oral mucosa.


Subject(s)
Excipients , Mouth Mucosa , Drug Compounding
3.
Actas dermo-sifiliogr. (Ed. impr.) ; 104(9): 738-756, nov. 2013. tab
Article in Spanish | IBECS | ID: ibc-127685

ABSTRACT

A pesar de la gran cantidad de productos disponibles producidos por la industria farmacéutica, hoy en día la formulación magistral sigue teniendo un papel muy importante en el tratamiento de las afecciones dermatológicas. Desde los inicios de la Dermatología se ha usado, siendo muy útil en el tratamiento de enfermedades para las que no se disponía de preparados farmacéuticos específicos; sin embargo, a medida que fueron apareciendo nuevos productos comercializados se puso en duda la utilidad de la formulación, cuestionando su seguridad, estabilidad y efectividad. Esto contrasta con la tendencia actual de recuperar la formulación, haciendo que vuelva a ocupar su lugar en la práctica dermatológica habitual. En el presente artículo revisamos las patologías en las que se usa con más frecuencia la formulación, sus utilidades e inconvenientes, la legislación actual al respecto en nuestro ámbito, aportando las últimas novedades descritas en cuanto a vehículos y principios activos disponibles (AU)


Compounding continues to play a key role in the treatment of skin conditions, despite the abundance of products made by the pharmaceutical industry. Right from the earliest days of dermatology, compounding proved very useful in the treatment of diseases for which no specific drugs were available. However, as new products came onto the market, this usefulness was called into question, and doubts over safety, stability, and effectiveness were raised. Today, compounding is regaining the place it once held in routine dermatological practice. We review the advantages and disadvantages of compounding, the most common indications, current legislation in our setting, and the latest developments in active ingredients and vehicles (AU)


Subject(s)
Humans , Acne Vulgaris/drug therapy , Drug Compounding , Psoriasis/drug therapy , Rosacea/drug therapy , Skin Diseases/drug therapy
4.
Actas Dermosifiliogr ; 104(9): 738-56, 2013 Nov.
Article in English, Spanish | MEDLINE | ID: mdl-22818830

ABSTRACT

Compounding continues to play a key role in the treatment of skin conditions, despite the abundance of products made by the pharmaceutical industry. Right from the earliest days of dermatology, compounding proved very useful in the treatment of diseases for which no specific drugs were available. However, as new products came onto the market, this usefulness was called into question, and doubts over safety, stability, and effectiveness were raised. Today, compounding is regaining the place it once held in routine dermatological practice. We review the advantages and disadvantages of compounding, the most common indications, current legislation in our setting, and the latest developments in active ingredients and vehicles.


Subject(s)
Drug Compounding , Skin Diseases/drug therapy , Acne Vulgaris/drug therapy , Humans , Psoriasis/drug therapy , Rosacea/drug therapy
5.
J Eur Acad Dermatol Venereol ; 19(5): 573-7, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16164711

ABSTRACT

BACKGROUND: Treatment of nail psoriasis is difficult. Several topical therapies have been employed with poor results because drug penetration is limited in this localization. Recently, a new formulation containing 8% clobetasol-17-propionate in a colourless nail lacquer vehicle has shown good results in the control of nail psoriasis. OBJECTIVE: To determine the efficacy and safety of 8% clobetasol-17-propionate in a lacquer vehicle in nail psoriasis. METHODS: Ten patients with both nail bed and matrix psoriasis were included in the study. They were treated with a colourless nail lacquer containing 8% clobetasol-17-propionate that was applied once daily for 21 days and then twice weekly for 9 months. RESULTS: Within 4 weeks of therapy there was a reduction of all the nail alterations, including nail pain. Therapeutic response was directly related to the length of therapy. The nail parameters that responded best to therapy were onycholysis, pitting and salmon patches. Subungual hyperkeratosis and splinter haemorrhages on the other hand had moderate and poor improvement, respectively. The treatment was well tolerated in all of the patients and there were no local (i.e. atrophy and sobreinfection) or systemic secondary effects. CONCLUSIONS: The formulation containing 8% clobetasol-17-propionate is a safe, effective and cosmetically highly acceptable treatment for nail bed and matrix psoriasis.


Subject(s)
Clobetasol/analogs & derivatives , Nails/drug effects , Psoriasis/drug therapy , Administration, Topical , Adult , Aged , Aged, 80 and over , Clobetasol/therapeutic use , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Hand Dermatoses/diagnosis , Hand Dermatoses/drug therapy , Humans , Male , Middle Aged , Prospective Studies , Psoriasis/diagnosis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...